Sugi Predict

Sugi Predict / Compounds / SCHEMBL976244

SCHEMBL976244

SCHEMBL976244

CC(C)(C)OC(=O)N1CCc2cc(C(=O)O)sc2C1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 2/20 0.55
▸ HDAC6 Q9UBN7 4/20 0.54
▸ ESR2 Q92731 1/20 0.53
▸ NR1H2 P55055 2/20 0.52
▸ DAO P14920 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ MAPK1 P28482 1/20 0.41
▸ P2RX3 P56373 1/20 0.41
▸ GRAMD1A Q96CP6 1/20 0.40
▸ FABP4 P15090 1/20 0.40
▸ FABP5 Q01469 1/20 0.40
▸ MKNK1 Q9BUB5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27081538 0.91 HDAC6 (0.59) ADORA1HDAC6ESR2NR1H2KDM4E
SCHEMBL8558763 0.91 ALDH1A1 (0.50) ADORA1HDAC6ESR2NR1H2DAO
SCHEMBL27141410 0.91 HDAC6 (0.58) ADORA1HDAC6ESR2NR1H2KDM4E
SCHEMBL743782 0.90 HDAC6 (0.54) ADORA1HDAC6ESR2NR1H2DAO
SCHEMBL23452601 0.88 ADORA1 (0.46) ADORA1HDAC6ESR2NR1H2DAO
SCHEMBL980137 0.85 ADORA1 (0.60) ADORA1HDAC6ESR2NR1H2ALDH1A1
SCHEMBL8560665 0.85 ALDH1A1 (0.50) ADORA1HDAC6ESR2NR1H2DAO
SCHEMBL29978014 0.84 NR1H2 (0.50) ADORA1HDAC6ESR2NR1H2KDM4E
SCHEMBL13985779 0.84 ESR2 (0.55) ADORA1HDAC6ESR2NR1H2KDM4E
SCHEMBL12869096 0.84 HDAC6 (0.51) ADORA1HDAC6ESR2NR1H2DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617801-B2 Tetrahydrothieno pyridine derivatives as DDRS inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-05-05 — — US disclosed
US-20250289807-A1 Inhibitors of ROCK2 GRAVITON BIOSCIENCE BV (NL) 2025-09-18 — — US disclosed
EP-4577537-A1 SUBSTITUTED BICYCLES AS HSET INHIBITORS Merck Patent GmbH (DE) 2025-07-02 — — EP disclosed
CN-120091998-A Substituted bicyclic rings as HSET inhibitors 默克专利股份公司 2025-06-03 — — CN disclosed
EP-4313994-B1 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-03-05 — — EP disclosed
EP-4514466-A1 INHIBITORS OF ROCK2 Graviton Bioscience BV (NL) 2025-03-05 — — EP disclosed
US-20240199635-A1 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-06-20 — — US disclosed
CN-111936475-B Immunomodulator, composition and preparation method thereof 贝达药业股份有限公司 2024-05-10 — — CN disclosed
WO-2024042007-A1 SUBSTITUTED BICYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2024-02-29 — — WO disclosed
EP-4313994-A1 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-02-07 — — EP disclosed
US-8440830-B2 Tetrahydro-fused pyridines as histone deacetylase inhibitors 4SC AG (DE) 2013-05-14 — — US disclosed
EP-2197552-B1 NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2012-11-21 — — EP disclosed
US-20110046157-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-24 — — US disclosed
US-20110046157-A1 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-24 — — US disclosed
US-20110021494-A1 NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2011-01-27 — — US disclosed
US-20110021494-A1 NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2011-01-27 — — US disclosed
WO-2010151317-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-12-29 — — WO disclosed
EP-2197552-A2 NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2010-06-23 — — EP disclosed
WO-2009037001-A2 NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS 4SC AG (DE) 2009-03-26 — — WO disclosed
US-7468371-B2 Tricyclic pyrazole kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-12-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12617801-B2 Tetrahydrothieno pyridine derivatives as DDRS inhibitors DDR1, DDR2, DDRGK1 ADORA1 1594/4885HDAC6 969/4885ESR2 1565/4885
US-20110021494-A1 NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS HDAC1, HDAC11, HDAC3 ADORA1 4630/4885HDAC6 11/4885ESR2 2520/4885
US-20250289807-A1 Inhibitors of ROCK2 ROCK2, ROCK1, RHOT2 ADORA1 4445/4885HDAC6 493/4885ESR2 1960/4885
US-20240199635-A1 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 ADORA1 2480/4885HDAC6 1647/4885ESR2 1497/4885
US-20110046157-A1 Substituted hydroxamic acids and uses thereof HDAC6, HDAC5, HDAC1 ADORA1 2928/4885HDAC6 1/4885ESR2 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.